Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Classical hematology 1

Conditions

Leukemia 14Myelodysplastic Syndromes 12Leukemia, Myelomonocytic, Chronic 8Anemia, Refractory, with Excess of Blasts 6Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myeloid, Acute 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Blast Crisis 3Anemia, Refractory 3Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Monocytic, Acute 2Burkitt Lymphoma 2Thrombocythemia, Essential 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Acute 1

Interventions

fludarabine phosphate 68Peripheral Blood Stem Cell Transplantation 58Cyclophosphamide 50Busulfan 47Tacrolimus 43Mycophenolic Acid 41Cyclosporine 34Antilymphocyte Serum 34Methotrexate 32Whole-Body Irradiation 30Filgrastim 24Radiotherapy 21Melphalan 21Cytarabine 20Flow Cytometry 18Etoposide 18Cord Blood Stem Cell Transplantation 17Methylprednisolone 16sargramostim 10Alemtuzumab 10Cytogenetic Analysis 9Thiotepa 8Polymerase Chain Reaction 8Therapeutics 7Psychiatric Rehabilitation 7In Situ Hybridization, Fluorescence 7Granulocyte Colony-Stimulating Factor 7merphos 6Immunoenzyme Techniques 6thymoglobulin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Abnormalities × Arsenic Trioxide × Myeloid × Clear all
NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡